Polyphor Ltd., a clinical stage, privately held Swiss specialty pharma company focused on the development of macrocycle drugs addressing antibiotic resistance and respiratory diseases, has completed a CHF 40 m private placement. Exisiting Polyphor investors, including the anchor investors Varuma AG and Ingro Finanz AG, contributed to 98% of the financing. VISCHER assisted Polpyhor in this transaction. The team at VISCHER was lead by Matthias Staehelin with Luzius Zumstein (both Corporate).